Omarigliptin (BioDeep_00000713536)
代谢物信息卡片
Omarigliptin
化学式: C17H20F2N4O3S (398.12241140000003)
中文名称: 奥格列汀
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CS(=O)(=O)N1C=C2CN(CC2=N1)C3CC(C(OC3)C4=C(C=CC(=C4)F)F)N
InChI: InChI=1S/C17H20F2N4O3S/c1-27(24,25)23-7-10-6-22(8-16(10)21-23)12-5-15(20)17(26-9-12)13-4-11(18)2-3-14(13)19/h2-4,7,12,15,17H,5-6,8-9,20H2,1H3/t12-,15+,17-/m1/s1
描述信息
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:134735
- KEGGdrug: D10317
- PubChem: 46209133
- DrugBank: DB11992
- ChEMBL: CHEMBL2105762
- CAS: 1226781-44-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Yan Zhang, Yang Liu, V Wee Yong, Mengzhou Xue. Omarigliptin inhibits brain cell ferroptosis after intracerebral hemorrhage.
Scientific reports.
2023 09; 13(1):14339. doi:
10.1038/s41598-023-41635-y. [PMID: 37658227] - Haidy E Michel, Mariam M Tadros, Moataz S Hendy, Shereen Mowaka, Bassam M Ayoub. Omarigliptin attenuates rotenone-induced Parkinson's disease in rats: Possible role of oxidative stress, endoplasmic reticulum stress and immune modulation.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
2022 Jun; 164(?):113015. doi:
10.1016/j.fct.2022.113015. [PMID: 35439590] - Zeyu Li, Hong Wang, Kanglin Wu, Lianfeng Zhang. Omarigliptin protects against nonalcoholic fatty liver disease by ameliorating oxidative stress and inflammation.
Journal of biochemical and molecular toxicology.
2021 Dec; 35(12):e22914. doi:
10.1002/jbt.22914. [PMID: 34533252] - Ling Li, Kelei Qian, Yuli Sun, Yong Zhao, Yun Zhou, Ying Xue, Xinyu Hong. Omarigliptin ameliorated high glucose-induced nucleotide oligomerization domain-like receptor protein 3 (NLRP3) inflammasome activation through activating adenosine monophosphate-activated protein kinase α (AMPKα) in renal glomerular endothelial cells.
Bioengineered.
2021 12; 12(1):4805-4815. doi:
10.1080/21655979.2021.1957748. [PMID: 34338149] - Makoto Ohara, Hiroe Nagaike, Tomoki Fujikawa, Yo Kohata, Maiho Ogawa, Takemasa Omachi, Risa Sasajima, Hirotoshi Chiba, Toshimasa Ara, Ayuka Sugawara, Munenori Hiromura, Michishige Terasaki, Yusaku Mori, Tomoyasu Fukui, Tsutomu Hirano, Hiroki Yokoyama, Sho-Ichi Yamagishi. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study.
Diabetes research and clinical practice.
2021 Sep; 179(?):108999. doi:
10.1016/j.diabres.2021.108999. [PMID: 34390762] - Bassam M Ayoub, Haidy E Michel, Shereen Mowaka, Moataz S Hendy, Mariam M Tadros. Repurposing of Omarigliptin as a Neuroprotective Agent Based on Docking with A2A Adenosine and AChE Receptors, Brain GLP-1 Response and Its Brain/Plasma Concentration Ratio after 28 Days Multiple Doses in Rats Using LC-MS/MS.
Molecules (Basel, Switzerland).
2021 Feb; 26(4):. doi:
10.3390/molecules26040889. [PMID: 33567615] - Shereen Mowaka, Nermeen Ashoush, Mariam Tadros, Noha El Zahar, Bassam Ayoub. Enhanced Extraction Technique of Omarigliptin from Human Plasma-Applied to Biological Samples from Healthy Human Volunteers.
Molecules (Basel, Switzerland).
2020 Sep; 25(18):. doi:
10.3390/molecules25184232. [PMID: 32942678] - Lokesh Jain, Anne S Y Chain, Daniel A Tatosian, Jeremy Hing, Julie A Passarell, Eunkyung A Kauh, Eseng Lai. Pharmacokinetic-pharmacodynamic (dipeptidyl peptidase-4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once-weekly administered omarigliptin.
British journal of clinical pharmacology.
2019 12; 85(12):2759-2771. doi:
10.1111/bcp.14103. [PMID: 31454094] - Xianying Wang, Xuejing Li, Suhui Qie, Yingying Zheng, Yang Liu, Guoqiang Liu. The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Medicine.
2018 Aug; 97(34):e11946. doi:
10.1097/md.0000000000011946. [PMID: 30142816] - Bassam M Ayoub, Shereen Mowaka, Marwa M Safar, Nermeen Ashoush, Mona G Arafa, Haidy E Michel, Mariam M Tadros, Mohamed M Elmazar, Shaker A Mousa. Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent.
Scientific reports.
2018 06; 8(1):8959. doi:
10.1038/s41598-018-27395-0. [PMID: 29895906] - Shiyao Xu, Dan Tatosian, Ian Mcintosh, Maria Caceres, Catherine Matthews, Koppara Samuel, Diana Selverian, Sanjeev Kumar, Eunkyung Kauh. Absorption, metabolism and excretion of [14C]omarigliptin, a once-weekly DPP-4 inhibitor, in humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2018 Jun; 48(6):584-591. doi:
10.1080/00498254.2017.1346333. [PMID: 28665228] - Ira Gantz, Taro Okamoto, Yuka Ito, Kotoba Okuyama, Edward A O'Neill, Keith D Kaufman, Samuel S Engel, Eseng Lai. A randomized, placebo- and sitagliptin-controlled trial of the safety and efficacy of omarigliptin, a once-weekly dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2017 11; 19(11):1602-1609. doi:
10.1111/dom.12988. [PMID: 28449368] - Meng-Fang Li, Xiao-Xia Hu, Ai-Qun Ma. Ultra-high pressure liquid chromatography-tandem mass spectrometry method for the determination of omarigliptin in rat plasma and its application to a pharmacokinetic study in rats.
Biomedical chromatography : BMC.
2017 Oct; 31(10):. doi:
10.1002/bmc.3975. [PMID: 28317144] - Ira Gantz, Liubov Sokolova, Lokesh Jain, Carol Iredale, Edward A O'Neill, Ziwen Wei, Raymond Lam, Shailaja Suryawanshi, Keith D Kaufman, Samuel S Engel, Eseng Lai. Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.
Clinical therapeutics.
2017 Oct; 39(10):2024-2037. doi:
10.1016/j.clinthera.2017.08.009. [PMID: 28923291] - R Ravi Shankar, Silvio E Inzucchi, Victoria Scarabello, Ira Gantz, Keith D Kaufman, Eseng Lai, Paulette Ceesay, Shailaja Suryawanshi, Samuel S Engel. A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Current medical research and opinion.
2017 10; 33(10):1853-1860. doi:
10.1080/03007995.2017.1335637. [PMID: 28547998] - Antonio Chacra, Ira Gantz, Geraldine Mendizabal, Lucila Durlach, Edward A O'Neill, Zachary Zimmer, Shailaja Suryawanshi, Samuel S Engel, Eseng Lai. A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.
International journal of clinical practice.
2017 Jun; 71(6):. doi:
10.1111/ijcp.12955. [PMID: 28449320] - Ronald Goldenberg, Ira Gantz, Paula J Andryuk, Edward A O'Neill, Keith D Kaufman, Eseng Lai, Yin Na Wang, Shailaja Suryawanshi, Samuel S Engel. Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Diabetes, obesity & metabolism.
2017 03; 19(3):394-400. doi:
10.1111/dom.12832. [PMID: 28093853] - Saori Tsuchiya, Evan Friedman, Carol Addy, Akira Wakana, Daniel Tatosian, Yuki Matsumoto, Hideyo Suzuki, Eunkyung Kauh. Single and multiple dose pharmacokinetics and pharmacodynamics of omarigliptin, a novel, once-weekly dipeptidyl peptidase-4 inhibitor, in healthy Japanese men.
Journal of diabetes investigation.
2017 Jan; 8(1):84-92. doi:
10.1111/jdi.12538. [PMID: 27182005] - Xueying Tan. Omarigliptin for the treatment of type 2 diabetes.
Endocrine.
2016 Oct; 54(1):24-31. doi:
10.1007/s12020-016-1011-9. [PMID: 27372109] - Carol Addy, Daniel A Tatosian, Xiaoli S Glasgow, Isaias Noel Gendrano, Christine McCrary Sisk, Eunkyung A Kauh, S Aubrey Stoch, John A Wagner. Effects of Age, Sex, and Obesity on the Single-Dose Pharmacokinetics of Omarigliptin in Healthy Subjects.
Clinical pharmacology in drug development.
2016 09; 5(5):374-82. doi:
10.1002/cpdd.255. [PMID: 27627193] - Carol Addy, Daniel Tatosian, Xiaoli S Glasgow, Isaias N Gendrano, Eunkyung Kauh, Ashley Martucci, Amy O Johnson-Levonas, Diana Selverian, Catherine Z Matthews, Marie Gutierrez, John A Wagner, S Aubrey Stoch. Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus.
Clinical therapeutics.
2016 Mar; 38(3):516-30. doi:
10.1016/j.clinthera.2015.12.020. [PMID: 26869191] - Wayne H-H Sheu, Ira Gantz, Menghui Chen, Shailaja Suryawanshi, Arpana Mirza, Barry J Goldstein, Keith D Kaufman, Samuel S Engel. Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
Diabetes care.
2015 Nov; 38(11):2106-14. doi:
10.2337/dc15-0109. [PMID: 26310692]